Neural precursor cells, method for the production and use thereof in neural defect therapy

• US 7,968,337 B2
• Filed: 03/14/2008
• Issued: 06/28/2011
• Est. Priority Date: 12/19/1997
• Status: Expired due to Fees

• Current Assignee: Oliver Bruestle
• Original Assignee: Oliver Bruestle
• Inventors: Bruestle, Oliver
• Primary Examiner(s): FALK, ANNE MARIE
• Application Number:
  US12/048,840
• Publication Number:
  US 20080213888A1
• Time in Patent Office: 1,201 Days
• Field of Search: None
• US Class Current: 435/377
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/13 Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/392 Sexual steroids
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0623 Stem cells

Abstract

The invention relates to isolated and purified neural precursor cells, to methods for the generation of such precursor cells in unlimited quantities from embryonic stem cells, and to their use for the therapy of neural defects, particularly in mammals, preferably in human beings, and for the generation of polypeptides.

Claims

1. A method for the generation of an isolated, non-tumorigenic cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal cells derived from the embryonic stem cell-derived neural precursor cells comprising:

(a) culturing mouse or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium, the first medium comprising basic fibroblast growth factor (bFGF);

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium, the second medium comprising bFGF and epidermal growth factor (EGF); and

(d) culturing the cells from (c) in a third growth factor-containing serum-free medium, the third medium comprising bFGF and platelet-derived growth factor (PDGF), to obtain the cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal cells derived from the embryonic stem cell-derived neural precursor cells.

2. The method according to claim 1, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

3. The method according to claim 1, wherein the cells of steps (c) and (d) grow as a monolayer.

4. The method according to claim 1, comprising cells with neuronal, astroglial or oligodendroglial properties.

5. The method according to claim 1, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

6. The method of claim 1, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

7. The method of claim 2, wherein the cell aggregates are embryoid bodies.

8. A method for the generation of an isolated, non-tumorigenic cell composition comprising neural spheres, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal cells derived from the embryonic stem cell-derived neural precursor cells comprising:

(a) culturing mouse or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor containing serum-free medium, the first medium comprising bFGF;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium, the second medium comprising bFGF and EGF to produce neural spheres consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal cells derived from the embryonic stem cellderived neural precursor cells,

thereby producing the isolated, non-tumorigenic cell composition comprising neural spheres.

9. The method according to claim 8, wherein the embryonic stem cells in (a) are in the form of cell aggregates.

10. The method of claim 9, wherein the cell aggregates are embryoid bodies.

11. The method of claim 8, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

12. The method according to claim 8, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

13. The method according to claim 8, further comprising:

(d) culturing the cells from step (c) in the second medium further comprising CNTF or T3 to direct differentiation of the precursor cells towards an astrocytic or an oligodendroglial fate.

14. The method according to claim 13, further comprising:

(e) culturing the cells from step (d) in a third medium comprising ciliary neurotrophic factor (CNTF) or T3, and isolation of the precursor cells with an astrocytic or an oligodendroglial fate.

15. The method according to claim 8, wherein the procedure is combined with cell separation and cell sorting techniques.

16. The method according to claim 8, wherein the purified precursor cells are suspended in a medium suitable for injection.